Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selepressin in vasopressor-dependent septic shock (phase 2b/3 adaptive trial)
2014-003973-41Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in septic shock comparing Selepressin plus standard care with Placebo plus standard care (2 arms). Primary endpoint: Vasopressor- and mechanical ventilator-free days (P&VFDs) up to Day 30. Started Jul 2015; status: completed.
02
Drugs
selepressin
03
Conditions
septic shock
Beyond the preview
Go deeper on 2014-003973-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003973-41.